Navigation Links
PharmAthene to Delay Release of Full Year 2007 Financial Results
Date:3/20/2008

ANNAPOLIS, Md., March 20 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, today reported the company will delay its earnings release for the full year ended December 31, 2007. The earnings release was previously scheduled for today, March 20, 2008. PharmAthene will schedule the new date and time of its earnings release and conference call at a later time.

The conference call originally scheduled to discuss earnings will occur at 4:30 pm E.T. today and will focus on the Avecia acquisition announced earlier today.

About PharmAthene, Inc.

PharmAthene (Amex: PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia(R) for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit http://www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
2. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
3. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
4. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
7. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
10. Flurizans Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimers Disease is Superior to That of Aricept
11. Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... ISPE announced today that ... the newly created position of Vice President of ... be responsible for stimulating ISPE’s revenue growth by ... Society’s Member-led and staff-driven business model, initiating integrated ... membership and product marketing. , “Barbara joins ISPE ...
(Date:5/16/2013)... 2013 In late 2012, Dr. Sarah Hart, ... doctors in China about Appearance Medicine . Although Dr. ... her first trip to lecture in China, and quite a ... Fuzhou, home to 12 and 7 million people respectively. Interest ... at this point in time. As Dr. Hart passed through ...
(Date:5/16/2013)... Cambridge Healthtech Institute will host its fifth annual ... Renaissance Waterfront Hotel in Boston, MA. The ten ... the current strategies and innovations for optimizing bioprocesses while ... the field will reveal how their work has resulted ... and efficiency. , “In this age of rapid innovation, ...
(Date:5/16/2013)...  HealthSparq, a trusted provider of healthcare transparency ... health plans, will debut a new benchmark study ... 2013 conference on June 13.  The presentation will ... insurance companies across the country are thinking about ... for increased healthcare transparency. This ...
Breaking Biology Technology:ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3
... - Oncothyreon Inc. (NASDAQ: ONTY ) (TSX: ONY) ... or $0.13 per basic and diluted share for the quarter ... $5.1 million or $0.26 per basic and diluted share for ... is primarily the result of the transfer of manufacturing activities ...
... - Bioniche Pharma, a leading developer and manufacturer ... (R) (edrophonium chloride injection, USP) and Enlon-Plus(R) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO )"The acquisition and launch ... and a commitment to bringing this important therapy ...
... announced that Chief Executive Officer, Mitchell H. Gold, M.D., ... Of The Year (R) 2009 Award in the ... the awards program recognizes entrepreneurs who demonstrate extraordinary success ... commitment to their businesses and communities. Mitchell Gold ...
Cached Biology Technology:Oncothyreon reports first quarter 2009 financial results 2Oncothyreon reports first quarter 2009 financial results 3Oncothyreon reports first quarter 2009 financial results 4Oncothyreon reports first quarter 2009 financial results 5Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest 2
(Date:5/16/2013)... MA -- Injectable nanoparticles developed at MIT may ... 1 diabetes to constantly monitor their blood-sugar levels ... were designed to sense glucose levels in the ... of insulin, thereby replacing the function of pancreatic ... Type 1 diabetes. Ultimately, this type of system ...
(Date:5/16/2013)... May 16, 2013 Integrated Biometrics patented ... a custom thin film transistor camera introduces Sherlock, ... roll image in the smallest and lightest form ... Appendix F Mobile ID FAP 45, Certified scanner ... in size and weight when compared to optical ...
(Date:5/16/2013)... where the entirety of an individual,s DNA is examined ... can cause health problems is a massively useful technology ... major ethical problems if used incorrectly, say new recommendations ... on line today (16 May 2013) in the ... on whole genome and on exome* sequencing and analysis ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2
... , Contributing to the diversity of plant species (avoiding ... using examples of native flora preferably instead of exotic species ... landscaped areas are some of the recommendations town councils should ... is the opinion of Paloma Carianos Gonzlez , researcher ...
... the University of Pittsburgh could expand the options for ... to more than one type of antipsychotic drug. The ... cortex could be a promising target for developing future ... action. The study will be published during the week ...
... armed forces and intelligence community seek out strategies that ... fronts, University of Houston researchers are developing innovative techniques ... the homeland. That pairing of tactical and technical expertise ... third Department of Defense Research Conference. "UH researchers ...
Cached Biology News:Expert recommends town councils to design low-allergy impact green spaces 2Pitt research identifies new target in brain for treating schizophrenia 2Research conference at UH to focus on US troops' needs, homeland security 2
... The ISOQUANT(R) Isoaspartate Detection Kit is ... residues in proteins and peptides, which can ... asparagine or rearrangement of aspartic acid residues ... does not depend on the monitoring of ...
Request Info...
Rb anti-Occludin (C-term GST)...
Request Info...
Biology Products: